Lisa Lopez Retires from Haemacure Corporation

BRAINTREE, Mass., Nov. 17, 2010 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today the planned retirement of Lisa Lopez, at the end of the Company’s fiscal year, effective April 1, 2011.

Ms. Lopez joined Haemonetics as General Counsel and Director Human Resources in 1988 and retires as Vice President Corporate Affairs. Over the 23 years of her Haemonetics career, in addition to serving as the Company’s Chief Legal Officer, Ms. Lopez’ role expanded to include at various times, Quality, Regulatory, Medical & Clinical Affairs, Investor Relations, Public Affairs, and Environmental Health & Safety. Ms. Lopez is a member of the Company’s Executive Council and has served as Secretary to the Board of Directors for over 20 years.

Brian Concannon, Haemonetics’ President and CEO said, “Lisa’s contributions to our business over the past 23 years are too numerous to count. She has played key roles at critical times in our history advancing our vision of blood management leadership. She leaves a lasting legacy with our employees, our customers, our shareholders, and most importantly the donors and patients who rely on our advances in blood management solutions. She will be sorely missed. We wish her and her husband, Victor, well in their retirement.”

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

CONTACT:

Bryanne Salmon

Tel. (781) 356-9613

bsalmon@haemonetics.com

SOURCE Haemonetics Corporation

MORE ON THIS TOPIC